LL-37 Polyclonal Antibody

LL-37 is a cationic ?-helical peptide expressed in human bone marrow, testis, granulocytes, gingival epithelium, and a variety of immune cells.{41499} It is produced by proteolytic cleavage of the cathelicidin human cationic antimicrobial protein of 18 kDa (hCAP18).{62129} LL-37 has antimicrobial and antiviral activity, and protein levels of LL-37 are increased in epithelial cells, macrophages, and neutrophils following bacterial infection in vitro.{41499,17198,41500,59280} It functions as a chemoattractant for human monocytes, neutrophils, and T cells, and induces chemokine secretion from epithelial cells in infected tissues.{41502,62129} LL-37 is a component of LPS-induced NETs produced from human neutrophils isolated from patients with systemic lupus erythrematosus (SLE) or individuals without SLE.{26640} It also enhances PMA- or S. aureus-induced formation of NETs.{33679} LL-37 can be citrullinated by protein arginine deiminase 2 (PAD2) and PAD4, a modification that reduces its antibacterial and antiviral activities.{35769,59280} Native, but not citrullinated, LL-37 prevents mortality in a mouse model of D-galactosamine-sensitized endotoxic shock.{35769} Cayman's LL-37 Polyclonal Antibody can be used for Western blot.